Following the announcement of the completion of the A round financing of 100 million yuan a few days ago, recently, Loqi Biotech announced the completion of the A+round financing of tens of millions of yuan again. This round of financing was led by the Hongyun Fund, a partnership between Huatai Zijin and Alibaba Health. Daoyuan Capital co-invested, and Haoyue Capital continued to serve as the exclusive financial adviser.

This round of financing will continue to be used for IND application and clinical development of two inhaled nanoantibody asthma treatment drugs, as well as preclinical development of other respiratory and autoimmune disease pipelines. In addition, Loki is also about to build a 500L GMP Pichia pastoris production plant that meets the requirements of clinical phase II sample preparation. In the next 1-2 years, three products will also enter the clinical research stage.

Dr. Wan Yakun, founder and general manager of Luoqi Biology, said

      Luoqi Biological is a nano-antibody biopharmaceutical research and development company focusing on the whole industrial chain. It is committed to the industrialization of innovative biopharmaceutical achievements and the research and development of targeted new drugs. It has established a complete nano-antibody new drug development system, effectively combining the early screening research and development of nano-antibody with the late process development of candidate drugs, forming a systematic and complete research and development system, which is at the leading level in the industry at home and even internationally. Thank you very much for your high recognition of our team and project! The success of this round of financing provides a strong guarantee for the rapid promotion of the company's new drug projects. We will continue to work in the field of respiratory and autoimmune diseases and accelerate the development of corresponding products.

Ms. Cao Qun, chairman of Huatai Zijin, said

      The founding team of Rocky Biology has rich R&D experience and international vision in the field of nanoantibodies. Based on the in-depth understanding of the advantages of nano-antibody proprietary drugs, the team carried out the variety development of innovative drug delivery methods for the indications of large market space, improved the accessibility and compliance of antibody drugs, and benefited patients at home and abroad. We are firmly optimistic about the future development of the nanoantibody industry and the unique potential of the company to become a leading enterprise in this field in China. Huatai Zijin will adhere to the investment philosophy of "growing together with entrepreneurs", and continue to help the company's development relying on its own resources.

Mr. Zhang Dafeng, chairman of Daoyuan Capital, said

     Loki Biology has a leading position in the field of nanoantibodies in China. It has systematically established Pichia pastoris CMC platform and nanoantibody rapid screening platform with core competitiveness, which lays a good foundation for giving full play to the compliance of nanoantibody delivery mode, low cost of production and ease of industrial transformation. We are full of expectations for the innovative drug project currently developed by Loki Biotech, and hope to be approved for marketing as soon as possible to meet the clinical needs of patients and reduce the cost burden of patients.

About Huatai Zijin

      Huatai Zijin is a wholly-owned subsidiary of Huatai Securities (601688. SH), which is engaged in private equity investment business. Relying on the advantages of the whole business chain of Huatai Securities, adhering to the investment concept of "growing together with entrepreneurs", and relying on rich financial and industrial resources, Huatai Zijin provides partners with all-round capital services. The company has a registered capital of 6 billion yuan and a management scale of more than 50 billion yuan. It has PE, M&A, FOF, industry and other funds. Huatai Zijin adheres to the industry orientation, based on solid industry research, deeply cultivates strategic emerging industries such as health care and TMT, and has accumulated rich industry experience and resources. The investment portfolio in the medical and health industry includes: Mindray Medical (300760. SZ), Pharmaceuticals (603259. SH/2359. HK), Rongchang Biological (09995. HK), Jidan Biological (603387. SH), Borray Pharmaceutical (688166. SH), Aidi Pharmaceutical (688488. SH), Shushi Biological (688399. SH), Shihe Gene, Shandong Shuyu, Pumen Technology, Emmel, Happy Oral, etc. The company has given full play to the capital operation advantages of the securities trading system, invested and promoted many enterprises to successfully land in the A/H share market, and provided all-round support around industry leaders, forming the industry's leading industrial investment and M&A capabilities.

About Daoyuan Capital

     Daoyuan Capital is a leading equity investment institution focusing on the field of medical and health care. It is committed to using the power of capital and industrial resources to help excellent medical and health enterprises grow rapidly, provide better medical products and services for the society, and improve human health. Daoyuan Capital manages 9 RMB funds and 2 USD funds. Its funds invest in 52 excellent projects. From 2019 to 2020, 8 enterprises were listed on the Hong Kong Stock Exchange and the Science and Technology Innovation Board, including Sano Medical (688108. SH), Weiwei Biological (01873. HK), Jinxin Reproductive (01951. HK), Anbiping (688393. SH), etc. By the end of 2021, Beikang Medical (02170. HK), invested by funds of Daoyuan Capital, was listed on the Hong Kong Stock Exchange. Two other enterprises had passed the municipal committee meetings on the Science and Technology Innovation Board and the Growth Enterprise Board, and one enterprise's application for IPO was accepted; It is estimated that in 2021 and 2022, Daoyuan Capital will have more than 10 investment companies listed on major stock exchanges at home and abroad.

About novamab

     Luoqi Biology was established in Shanghai International Medical Park in 2017, and was recognized as a national high-tech enterprise in 2020. It has a research and development base of more than 2500 square meters and a unique camel breeding base. Luoqi Biological has independently created five core technology platforms based on nano-antibody: nano-antibody rapid screening platform, Pichia pastoris CMC process development platform, inhaled macromolecular drug research and development platform, nano-antibody long-acting platform and nano-antibody dual-antibody platform. Each platform has very unique industry advantages, which can quickly screen out nano-antibody drugs with drug activity and rapidly industrialization. Dr. Wan Yakun, the founder of the company, is a pioneer in the field of nanoantibody in China. He served as the director of the first nanoantibody research center in China and applied for more than 40 invention patents related to nanoantibody.